Trial reportLeukemia2005
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
Trial report in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01429610 (Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia), which is not on this map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
Who cites it
46 citing papers in PubMed, 144 citations in OpenAlex.
- Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.Haematologica · 2015Trial
- Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Trial
- CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.Journal of hematology & oncology · 2026Observational
- Next-Generation Sequencing for Minimal Residual Disease Detection in Pediatric Acute Lymphoblastic Leukemia: Technological Advances, Clinical Translations and Current Challenges.Current issues in molecular biology · 2026Review
- Real-time immunophenotypic shifts in pediatric B lymphoblastic leukemia providing implications for minimal residual disease detection.Advances in laboratory medicine · 2025Article
- Article
- Analysis of Antigen Expression in T-Cell Acute Lymphoblastic Leukemia by Multicolor Flow Cytometry: Implications for the Detection of Measurable Residual Disease.International journal of molecular sciences · 2025Article
- The influence of cytotoxic drugs on the immunophenotype of blast cells in paediatric B precursor acute lymphoblastic leukaemia.Radiology and oncology · 2024Article
- The Significance of CD20 Intensity Variance in Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia.Journal of clinical medicine · 2023Article
- A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2022Article
- Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions.Cancers · 2021Review
- Flow Cytometric Minimal Residual Disease Analysis in Acute Leukemia: Current Status.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Review
- Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.Frontiers in oncology · 2019Review
- Novel Therapies in Acute Lymphoblastic Leukemia.Current hematologic malignancy reports · 2018Review
- [Expert consensus on minimal residual disease detection of acute leukemia and plasma cell neoplasms by multi-parameter flow cytometry].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.Mediterranean journal of hematology and infectious diseases · 2016Review
- Minimal Residual Disease Detection and EvolvedFrontiers in immunology · 2016Article
- Review
- Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.Medical oncology (Northwood, London, England) · 2014Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of minimal residual disease (MRD) by flow cytometry is considered to be based on the reproducibility of the leukemic immunophenotype detected at diagnosis. However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment. Hence, we investigated this in 30 children with B-cell precursor ALL consecutively enrolled in the AIEOP-BFM ALL 2000 protocol. Quantitative expression of seven antigens useful in MRD monitoring was studied at diagnosis and compared to that measured at different time points of remission induction therapy. Downmodulation in the expression of CD10 and CD34 occurred at follow-up. By contrast, upmodulation of CD19, CD20, CD45RA, and CD11a was observed, while the expression of CD58 remained stable. Despite this, we could unambiguously discriminate leukemic cells from normal residual B cells. This holds true when bone marrow (BM) samples from similarly treated T-ALL patients, but not from healthy donors, were used as reference. Our results indicate that immunophenotypic modulation occurs in ALL during the early phases of BFM-type protocols. However, the accuracy of MRD detection by flow cytometry seems not negatively affected if adequate analysis protocols are employed. Investigators should take this phenomenon into account in order to avoid pitfalls in flow cytometric MRD studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.